Lightstone Ventures related stories
All articles and analysis
Precision medicine company Gemini Therapeutics attracts $42.5 mlnCambridge, Massachusetts-based Gemini Therapeutics, a new precision medicine company , has closed $42.5 million in Series A financing. Atlas Venture, Lightstone Ventures and OrbiMed led the round.
- Hearing aid maker Earlens Corp pulls in $118 mln
Earlens Corporation Inc, a hearing aid maker, has raised $118 million in a funding tally. Included in that figure is $73 million in Series C preferred stock financing and a debt facility with CRG LP for up to $45 million. Vertex Healthcare led the Series C round with participation from other investors that included Windham Venture Partners, Sightline Partners, New Enterprise Associates, Aisling Capital, Lightstone Ventures and Medtronic.
- Cerevance raises another $5 mln
The Dementia Discovery Fund, which is managed by SV Life Sciences, has invested $5 million in the initial financing round of Cerevance. Cerevance, a drug discovery company with offices in Boston and Cambridge, U.K., has raised $36 million in commitments of equity and non-dilutive capital from Lightstone Ventures and Takeda Pharmaceuticals Co Ltd.
- Cerevance takes in $36 mln
Newly launched neuroscience company Cerevance has raised $36 million in funding. The company's investors are Takeda Pharmaceutical Company Limited and Lightstone Ventures.
- Carrick Therapeutics raises $95 mln
Carrick Therapeutics Ltd has raised $95 million in funding led by ARCH Venture Partners and Woodford Investment Management. Investors include Cambridge Enterprise, Evotec AG, Google Ventures, Lightstone Venture and Cambridge Innovation Capital. Carrick is a European oncology company.